Richard Locicero
Medical Oncology · Gainesville, GANPI 1578543948
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,599 of the $8,601 with a category attached, or 88.3%. It is spread thinly across 54 manufacturers, the largest accounting for just 8.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,379 and has fallen 98.7% since, to $32 in 2025.
Across 416 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$694
- GSK$652
- Merck$615
- AstraZeneca$476
- Genentech USA, Inc.$466
- Bristol Myers Squibb$412
- plus $5K from 48 others
Across 10 payments — averaging $2476.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$25K
What the payments were for
- Consulting fees$4305%
- Speaking & faculty fees$4255%
- Food & beverage$7,59988%
- Education$1472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BLENREP$430
How this compares
$8,601 in reported general payments places this provider in the 55th percentile of 68 medical oncology providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 11 | $183,935 |
| EliquisApixaban | 12 | $5,862 |
| Anastrozole | 47 | $1,032 |
| Letrozole | 44 | $954 |
| Pantoprazole Sodium | 14 | $265 |
| Quetiapine Fumarate | 23 | $234 |
| Potassium Chloride | 15 | $217 |
| Haloperidol | 20 | $173 |
| Amlodipine Besylate | 19 | $139 |
| Tamoxifen Citrate | 13 | $136 |
| Levothyroxine Sodium | 14 | $101 |
| Alendronate Sodium | 11 | $72 |
| Prednisone | 13 | $67 |
| Trazodone Hcl | 13 | $29 |
| Tamsulosin Hcl | 12 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $476 | $183,93511 claims |
| PfizerEliquis | $327 | $5,86212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Gainesville
- Andrew JohnsonGainesville$22K
- Charles NashGainesville$19K
- Venumadhav KotlaGainesville$18K
- Yamin SunGainesville$17K
- Shravanti MacherlaGainesville$14K
- Timothy CareyGainesville$14K
- Devi SampatGainesville$13K
- Jennifer AndersonGainesville$12K
- Nancy SteadGainesville$2K
- Samir KhleifAugusta$337K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.